Stay updated on Open-Label Surufatinib in EU NET Patients Clinical Trial
Sign up to get notified when there's something new on the Open-Label Surufatinib in EU NET Patients Clinical Trial page.

Latest updates to the Open-Label Surufatinib in EU NET Patients Clinical Trial page
- CheckyesterdayChange DetectedThe page has been updated to reflect a new timeline for the Open-Label Phase 2 Study of Surufatinib in European Patients with Neuroendocrine Tumours, with new dates for the study and the removal of previous recruitment statuses.SummaryDifference3%
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check44 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check51 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check65 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check72 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in this functionality.SummaryDifference0.3%
Stay in the know with updates to Open-Label Surufatinib in EU NET Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Open-Label Surufatinib in EU NET Patients Clinical Trial page.